Nano P42T - Medesis Pharma
Alternative Names: Nano-P42TLatest Information Update: 02 Feb 2024
At a glance
- Originator Medesis Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 11 Jan 2024 Preclinical trials in Huntington's disease in France (unspecified route) (Medesis Pharma pipeline, January 2024)